@entity32292 is an oral y-selective retinoid agonist. In @entity2415 models, @entity32292 reduced @entity32 , promoted structural repair and functional improvement. REPAIR (Retinoid treatment of @entity2415 in @entity1 on the a(1)-antitrypsin International Registry), was an investigator-initiated, double-blind, placebo-controlled randomised study to assess the safety and efficacy of 5 mg  day(-1) @entity32292 given for 1 year to 262 @entity1 with severe a(1)-antitrypsin deficiency and @entity2415 confirmed by computed tomography. Change in volume-adjusted 15th percentile point lung density from baseline in 1 year was the primary end-point; functional end-points were also regularly assessed. We randomly assigned 133 and 129 @entity1 to placebo or @entity32292 , respectively. Both groups were well matched for all baseline characteristics, including respiratory medications. 88% and 85% of @entity1 completed 1 year of treatment with placebo and @entity32292 , respectively. @entity32292 was generally well tolerated. In the study completers population, the placebo-corrected difference of lung density was -0.45 HU at week 28 (p=0.64) and -0.25 HU at week 52 (p=0.94). A nonsignificant treatment difference in most functional parameters of the lung in favour of the drug was observed over time suggesting potential pharmacological effects of @entity32292 . @entity32292 5 mg  day(-1) over 1 yr failed to show a significant benefit on lung density in moderate-to-severe @entity2415 secondary to severe a(1)-antitrypsin deficiency.

Randomised controlled trial for XXXX with a selective agonist of the y-type retinoic acid receptor.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity2415 :: ('MESH:D004646', 'Disease') :: ['Emphysema', 'emphysema', 'animal emphysema'] @entity32292 :: ('MESH:C546535', 'Chemical') :: ['palovarotene', 'Palovarotene']
@entity2415 :: (MESH:D004646,Disease) :: ['emphysema']
